Patents by Inventor Jill A. Macoska

Jill A. Macoska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • URINARY RNA SIGNATURES IN RENAL CELL CARCINOMA (RCC)
    Publication number: 20220364178
    Abstract: Methods of diagnosing, predicting risk of recurrence, and treating Renal Cell Carcinoma (RCC), e.g., clear cell Renal Cell Carcinoma (RCC).
    Type: Application
    Filed: August 13, 2020
    Publication date: November 17, 2022
    Inventors: Jill A. Macoska, Justin Cotellessa, Manoj Bhasin
  • Compositions and methods for detecting and treating prostate disorders
    Patent number: 7598028
    Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: October 6, 2009
    Assignee: The Regents of the University of Michigan
    Inventor: Jill A. Macoska
  • Compositions and Methods for Detecting And Treating Prostate Disorders
    Publication number: 20080206766
    Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).
    Type: Application
    Filed: November 28, 2007
    Publication date: August 28, 2008
    Applicant: The Regents of the University of Michigan
    Inventor: Jill A. Macoska